The ERK and p38MAPK Pathways as Targets for Anti-Inflammatory Therapy

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 6, Iss. 1, 2007-01 ,pp. : 85-97

Bentham Science Publishers

Access to resources Recommend Favorite

SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance

By Baranck M.   Bohacova V.   Kvackajova J.   Hudecova S.   Krizanova O.   Breier A.  

European Journal of Pharmaceutical Sciences, Vol. 14, Iss. 1, 2001-08 ,pp. : 29-36

Elsevier

Access to resources Recommend Favorite

The p38 MAPK Inhibitor SB203580 Blocks Adenosine A₁ Receptor-Induced Attenuation of In Vivo Myocardial Stunning

By Yoshimura Yukihiro   Kristo Gentian   Keith Byron   Jahania Salik   Mentzer Robert   Lasley Robert  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 6, 2004-11 ,pp. : 433-440

Springer Publishing Company

Access to resources Recommend Favorite

Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model

By Tamhane Mitalee   Chakilam Ananthsrinivas R.   Jayaraj Andrew   Thakkar Vineet   Taft David R.  

Drug Development and Industrial Pharmacy, Vol. 36, Iss. 3, 2010-03 ,pp. : 315-322

Informa Healthcare

Access to resources Recommend Favorite

5-Amino-2-carbonylthiophene derivatives for use as p38 MAPK inhibitors in the treatment of inflammatory diseases

By Boehm Jeffrey  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 10, 2005-10 ,pp. : 1471-1476

Informa Healthcare

Access to resources Recommend Favorite